A5018152558- Platelet Disorders and Treatments
- Hemophilia Treatment and Research
- Blood groups and transfusion
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Blood transfusion and management
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Blood Coagulation and Thrombosis Mechanisms
- Venous Thromboembolism Diagnosis and Management
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Complement system in diseases
- Chronic Myeloid Leukemia Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiac Imaging and Diagnostics
- Ultrasound and Hyperthermia Applications
- COVID-19 Clinical Research Studies
- Eicosanoids and Hypertension Pharmacology
- Chronic Lymphocytic Leukemia Research
- Diet and metabolism studies
- Thyroid Cancer Diagnosis and Treatment
- Systemic Sclerosis and Related Diseases
- Blood donation and transfusion practices
- Monoclonal and Polyclonal Antibodies Research
- Autoimmune Bullous Skin Diseases
- Renal function and acid-base balance
- Bipolar Disorder and Treatment
Ludwig-Maximilians-Universität München
2015-2024
LMU Klinikum
2015-2023
CTI BioPharma (United Kingdom)
2021
Heidelberg University
2001
BackgroundAcquired hemophilia A (AHA) is an autoimmune bleeding disorder caused by neutralizing antibodies against coagulation factor VIII. Immunosuppressive therapy (IST) standard of care to eradicate autoantibody production and protect from further but carries a risk severe infection mortality in frail patients with AHA. Recently, emicizumab has been studied for its potential reduce the need early aggressive IST.ObjectivesTo compare outcomes 2 studies that used either IST (GTH-AH 01/2010;...
The prognosis of acquired haemophilia A (AHA) is severe and treatment options are limited. Emicizumab a novel bispecific humanized monoclonal antibody in the inherited AHA with inhibitors. An 83-year-old patient congestive heart failure high risk for thromboembolic cardiac events who had initially been treated successfully steroids substitution recombinant B-domain-deleted porcine FVIII developed bleeding complications secondary increase inhibitor titres after 4 weeks treatment. Conventional...
Abstract Ibrutinib and acalabrutinib are approved for B cell malignancies novel Bruton's tyrosine kinase (Btk) inhibitors undergo clinical testing also in cell-driven autoimmune disorders. Btk platelets mediates platelet activation via glycoprotein (GP) VI, which is crucial atherosclerotic plaque-induced thrombus formation. This can be selectively inhibited by inhibitors. Since patients on second-generation apparently show less bleeding than ibrutinib, we compared the effects of ibrutinib...
Background: Recombinant von Willebrand factor (rVWF), which was licensed in the United States 2015, has multimeric distribution of freshly secreted VWF with ultralarge (UL) and high molecular weight multimers (HMWM) from endothelial cells megakaryocytes since it never been exposed to ADAMTS13 or any other proteolytic enzyme. Measurement closure time (CT) using platelet function analyzer-200 (PFA-200) is highly sensitive presence UL added concentrates. The PFA-200 fully automated can be used...
Abstract Introduction A dedicated emicizumab assay based on the modified one‐stage factor VIII (FVIII) (mOSA) is mainly available in haemophilia treatment centres (HTC). method to estimate plasma levels a widely would be desirable, especially for emergency situations. Aim level approximation (ELA) using routine FVIII activity measurement with standard (sOSA) was developed and evaluated. Method Within this pilot study, 59 samples from patients severe (n = 8) without inhibitors under were...
Coagulopathy has proven to be a common complication of the novel coronavirus SARS-CoV-2, with evidence elevated D-dimers and fibrin degradation products associated an increased incidence thromboembolism. Despite emerging describing coagulopathy its clinical relevance in COVID-19, fewer studies have addressed potential role empiric therapeutic anticoagulation this setting. We report case patient admitted our intensive care unit (ICU) severe acute respiratory distress syndrome (ARDS) secondary...
Differentiated thyroid carcinoma (DTC) in childhood and during adolescence is extremely rare. Pediatric DTC commonly presents with advanced disease at diagnosis including a high prevalence of cervical lymph node metastases pulmonary metastases. Studies children are limited. Therefore, we aimed to evaluate the initial presentation, effectiveness radioiodine therapy (RIT), long-term outcome prepubertal comparison pubertal/postpubertal patients.Eighty-five pediatric young patients aged 6.4 21.9...
Recently we reported that in vitro addition of recombinant von Willebrand factor (rVWF; Veyvondi) to blood matrix patients with severe VWD led a dose-dependent reduction closure time the PFA 200 (Pekrul, Kragh et al, 2018). The relevant components are ultra-large multimers (ULM) VWF, because conventional plasma products and rVWF without ULM did not normalize primary hemostasis measuring our vivo. Previous studies showed administration DDAVP type I release endogenous VWF normalization (Weston...
Introduction Optimized haemophilia care with its zero-bleed strategy is critical for patient outcomes. Various therapeutic options are available treatment individualization, offering higher trough factor levels and a reduction in burden. However, does switching from conventional to novel concentrates (CFC, FC) extended half-life (EHL) improve the overall number of bleeds (NBs) real-world cohort?
Störungen des physiologischen Gleichgewichts im Gerinnungssystem können bei Kindern wie Erwachsenen angeboren oder erworben auftreten und zu Blutungen und/oder Thrombosen führen. In der klinischen Präsentation, Diagnostik, Befundinterpretation Therapie gilt es allerdings einige Besonderheiten Kindesalters beachten.
Objectives: Emicizumab (Emi) is a humanised bispecific antibody with novel mechanism of action (MoA) - it bridges factor X (FX) and activated IX (FIXa) to restore haemostatic function; due its biochemical properties, Emi interferes various standard coagulation assays. approved for prophylactic treatment in people haemophilia A (PwHA) FVIII inhibitors. The aim herein provide closer view available data concerning the questions: how does interfere assays? Which assays can be applied clinical routine?
We characterized the clinical efficacy of a von Willenbrand factor (VWF) concentrate with low VIII content for patient suffering from severe type 1 Willebrand disease (VWD) concomitant high risk ischemic myocardial infarction. A male patient, aged 86 has been scheduled elective surgery basal cell carcinoma resection and consecutive skin transplantation. Secondary Aspirin prophylaxis due to former coronary stent implantation stopped 5 days preoperatively reduce bleeding risk. Furthermore we...